PLR、NLR、SII及HALP在肺癌预后评估中的研究进展
Research Progress of PR, NLR, SII and HALP in Prognostic Evaluation of Lung Cancer
DOI: 10.12677/acm.2025.1561832, PDF,    科研立项经费支持
作者: 黄艳桃*：右江民族医学院研究生学院，广西 百色；李 卫#：右江民族医学院研究生学院，广西 百色；广西壮族自治区人民医院健康管理中心，广西 南宁
关键词: 肺癌；炎症；PLR；NLR；SII；HALP；Lung Cancer； Inflammation； PLR； NLR； SII； HALP
摘要: 炎症在肺癌发生、发展和预后中扮演着重要的角色。作为肿瘤微环境的重要组成部分，炎症细胞及其介导的免疫反应与肺癌的预后密切相关。肺癌作为全球发病率和死亡率最高的恶性肿瘤之一，其预后评估始终是临床诊疗的关键环节。近年来，随着肿瘤微环境研究的深入，血小板/淋巴细胞(PLR)、中性粒细胞/淋巴细胞(NLR)、血小板 × 中性粒细胞/淋巴细胞(SII)、血红蛋白 × 白蛋白 × 淋巴细胞/血小板计数(HALP)等新型炎症标志物逐渐成为研究热点。这些指标不仅检测简便、成本低廉，还能动态反映机体免疫失衡与炎症状态，在肺癌的预后评估中展现出独特价值。本文将围绕这些标志物在肺癌预后中的研究进展展开综述。
Abstract: Inflammation plays an important role in the occurrence, development, and prognosis of lung cancer. As an important component of the tumor microenvironment, inflammatory cells and their mediated immune responses are closely related to the prognosis of lung cancer. Lung cancer is one of the malignant tumors with the highest incidence rate and mortality in the world, and its prognosis evaluation is always a key link in clinical diagnosis and treatment. In recent years, with the in-depth study of the tumor microenvironment, novel inflammatory markers such as the platelet/lymphocyte (PLR), neutrophil/lymphocyte (NLR), platelet × neutrophil/lymphocyte (SII), and hemoglobin × albumin × lymphocyte/platelet count (HALP) have gradually become research hotspots. These indicators are not only easy to detect and cost-effective, but also dynamically reflect the immune imbalance and inflammatory status of the body, demonstrating unique value in the prognosis evaluation of lung cancer. This article will review the research progress of these biomarkers in the prognosis of lung cancer.
文章引用：黄艳桃, 李卫. PLR、NLR、SII及HALP在肺癌预后评估中的研究进展[J]. 临床医学进展, 2025, 15(6): 1122-1127. https://doi.org/10.12677/acm.2025.1561832

参考文献

[1] 肺癌筛查与早诊早治方案(2024年版) [J]. 全科医学临床与教育, 2024, 22(9): 772-776.
[2] Fernandes, Q., Inchakalody, V.P., Bedhiafi, T., Mestiri, S., Taib, N., Uddin, S., et al. (2024) Chronic Inflammation and Cancer; the Two Sides of a Coin. Life Sciences, 338, Article 122390. [Google Scholar] [CrossRef] [PubMed]
[3] Greten, F.R. and Grivennikov, S.I. (2019) Inflammation and Cancer: Triggers, Mechanisms, and Consequences. Immunity, 51, 27-41. [Google Scholar] [CrossRef] [PubMed]
[4] Sylman, J.L., Mitrugno, A., Atallah, M., Tormoen, G.W., Shatzel, J.J., Tassi Yunga, S., et al. (2018) The Predictive Value of Inflammation-Related Peripheral Blood Measurements in Cancer Staging and Prognosis. Frontiers in Oncology, 8, Article 78. [Google Scholar] [CrossRef] [PubMed]
[5] Nøst, T.H., Alcala, K., Urbarova, I., Byrne, K.S., Guida, F., Sandanger, T.M., et al. (2021) Systemic Inflammation Markers and Cancer Incidence in the UK Biobank. European Journal of Epidemiology, 36, 841-848. [Google Scholar] [CrossRef] [PubMed]
[6] Li, S., Lu, Z., Wu, S., Chu, T., Li, B., Qi, F., et al. (2023) The Dynamic Role of Platelets in Cancer Progression and Their Therapeutic Implications. Nature Reviews Cancer, 24, 72-87. [Google Scholar] [CrossRef] [PubMed]
[7] Mantovani, A., Allavena, P., Sica, A. and Balkwill, F. (2008) Cancer-Related Inflammation. Nature, 454, 436-444. [Google Scholar] [CrossRef] [PubMed]
[8] Zhou, K., Cao, J., Lin, H., Liang, L., Shen, Z., Wang, L., et al. (2022) Prognostic Role of the Platelet to Lymphocyte Ratio (PLR) in the Clinical Outcomes of Patients with Advanced Lung Cancer Receiving Immunotherapy: A Systematic Review and Meta-Analysis. Frontiers in Oncology, 12, Article 962173. [Google Scholar] [CrossRef] [PubMed]
[9] Liu, N., Mao, J., Tao, P., Chi, H., Jia, W. and Dong, C. (2022) The Relationship between NLR/PLR/LMR Levels and Survival Prognosis in Patients with Non-Small Cell Lung Carcinoma Treated with Immune Checkpoint Inhibitors. Medicine, 101, e28617. [Google Scholar] [CrossRef] [PubMed]
[10] Kutlu, Y., Aydin, S.G., Bilici, A., Oven, B.B., Olmez, O.F., Acikgoz, O., et al. (2023) Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio as Prognostic Markers in Patients with Extensive-Stage Small Cell Lung Cancer Treated with Atezolizumab in Combination with Chemotherapy. Medicine, 102, e33432. [Google Scholar] [CrossRef] [PubMed]
[11] Hinterleitner, C., Strähle, J., Malenke, E., et al. (2021) Platelet PD-L1 Reflects Collective Intratumoral PD-L1 Expression and Predicts Immunotherapy Response in Non-Small Cell Lung Cancer. Nature Communications, 12, Article No. 7005.
[12] Wang, J., Li, H., Xu, R., et al. (2022) The MLR, NLR, PLR and D-Dimer Are Associated with Clinical Outcome in Lung Cancer Patients Treated with Surgery. BMC Pulmonary Medicine, 22, Article No. 104.
[13] 李甜甜, 葛静, 徐晓玲. 血清炎症标志物对肺癌患者远处转移的预测价值[J]. 临床肺科杂志, 2024(12): 1876-1880.
[14] Hedrick, C.C. and Malanchi, I. (2022) Neutrophils in Cancer: Heterogeneous and Multifaceted. Nature Reviews Immunology, 22, 173-187.
[15] Casbon, A., Reynaud, D., Park, C., Khuc, E., Gan, D.D., Schepers, K., et al. (2015) Invasive Breast Cancer Reprograms Early Myeloid Differentiation in the Bone Marrow to Generate Immunosuppressive Neutrophils. Proceedings of the National Academy of Sciences, 112, E566-E575. [Google Scholar] [CrossRef] [PubMed]
[16] Nishizawa, M., Tsuchiya, M., Watanabe-Fukunaga, R., et al. (1990) Multiple Elements in the Promoter of Granulocyte Colony-Stimulating Factor Gene Regulate Its Constitutive Expression in Human Carcinoma Cells. Journal of Biological Chemistry, 265, 5897-5902.
[17] Wan, Y., Chen, H., Liu, X., Gu, W. and Lu, Y. (2022) Elevated Pretreatment Neutrophil-to-Lymphocyte Ratio Indicate Low Survival Rate in Apatinib-Treated Patients with Non-Small Cell Lung Cancer: A Strobe-Compliant Article. Medicine, 101, e32043. [Google Scholar] [CrossRef] [PubMed]
[18] Bi, H., Ren, D., Xiao, Y., Zhou, Y., Yi, B., Han, W., et al. (2024) Prognostic Implications of Neutrophil-to-Lymphocyte Ratio in Patients with Extensive-Stage Small Cell Lung Cancer Receiving Chemoimmunotherapy: A Multicenter, Real-World Study. Thoracic Cancer, 15, 559-569. [Google Scholar] [CrossRef] [PubMed]
[19] Bryant, A.K., Sankar, K., Strohbehn, G.W., et al. (2022) Prognostic and Predictive Value of Neutrophil-to-Lymphocyte Ratio with Adjuvant Immunotherapy in Stage III Non-Small-Cell Lung Cancer. Lung Cancer, 163, 35-41.
[20] Zhao, T. (2022) Prognostic Assessment of CReactive Protein and Neutrophil to Lymphocyte Ratio in Patients with Non-Small Cell Lung Cancer. Wiener klinische Wochenschrift, 134, 705-711.
[21] Delikgoz Soykut, E., Kemal, Y., Karacin, C., Karaoglanoglu, O., Kurt, M. and Aytac Arslan, S. (2021) Prognostic Impact of Immune Inflammation Biomarkers in Predicting Survival and Radiosensitivity in Patients with Non-Small-Cell Lung Cancer Treated with Chemoradiotherapy. Journal of Medical Imaging and Radiation Oncology, 66, 146-157. [Google Scholar] [CrossRef] [PubMed]
[22] Li, X., Hu, P., Liu, J., Zhang, J. and Liu, Q. (2020) Systemic Immune-Inflammation Index Predicted Overall Survival and Radiosensitivity in Advanced Non-Small-Cell Lung Cancer. Future Oncology, 16, 103-115. [Google Scholar] [CrossRef] [PubMed]
[23] Zhang, Y., Chen, Y., Guo, C., Li, S. and Huang, C. (2025) Systemic Immune-Inflammation Index as a Predictor of Survival in Non-Small Cell Lung Cancer Patients Undergoing Immune Checkpoint Inhibition: A Systematic Review and Meta-Analysis. Critical Reviews in Oncology/Hematology, 210, Article 104669. [Google Scholar] [CrossRef] [PubMed]
[24] Huang, W., Luo, J., Wen, J. and Jiang, M. (2022) The Relationship between Systemic Immune Inflammatory Index and Prognosis of Patients with Non-Small Cell Lung Cancer: A Meta-Analysis and Systematic Review. Frontiers in Surgery, 9, Article 898304. [Google Scholar] [CrossRef] [PubMed]
[25] Huo, J., Wang, Y., Su, J., Liu, S., Osoegawa, A., Jia, Z., et al. (2024) Correlation of Hemoglobin, Albumin, Lymphocyte, and Platelet Score with Prognosis in Patients with Stage III Squamous Lung Cancer. Journal of Thoracic Disease, 16, 7016-7028. [Google Scholar] [CrossRef] [PubMed]
[26] Gao, S., Huang, Q., Wei, S., Lv, Y., Xie, Y. and Hao, Y. (2024) Prognostic Nomogram Based on Pre-Treatment HALP Score for Patients with Advanced Non-Small Cell Lung Cancer. Clinics, 79, Article 100371. [Google Scholar] [CrossRef] [PubMed]
[27] Su, H., Yu, C., Sun, G., Wang, B., Gao, Y., Liu, X., et al. (2024) Prognostic Value of Immunotherapy in Advanced NSCLC Based on Baseline and Dynamic Changes in HALP. Biomolecules and Biomedicine, 25, 29-41. [Google Scholar] [CrossRef] [PubMed]

为你推荐